Hardenberg, Jost von and Borkowetz, Angelika and Siegel, Fabian and Kornienko, Kira and Westhoff, Niklas and Jordan, Tobias B. and Hoffmann, Manuela and Drerup, Martin and Lieb, Verena and Taymoorian, Kasra and Schostak, Martin and Ganzer, Roman and Hoefner, Thomas and Cash, Hannes and Bruendl, Johannes (2021) Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Large Multicenter Cohort Study. EUROPEAN UROLOGY FOCUS, 7 (5). pp. 1002-1010. ISSN , 2405-4569
Full text not available from this repository. (Request a copy)Abstract
Background: Focal therapy (FT) with its favorable side-effect profile represents an option between active surveillance and traditional whole-gland treatment in localized prostate cancer (PCa). Consensus statements recommend eligibility criteria based on magnetic resonance imaging (MRI)-targeted and systematic combination biopsy. Objective: To estimate the future potential of FT by analyzing the number of men eligible for FT among all men with biopsy-proven PCa and to judge the potential of different energy sources. Design, setting, and participants: Consensus criteria on FT were analyzed. Patients with biopsy-proven PCa from six tertiary referral hospitals and one outpatient practice in Germany had received a software-based combination biopsy. Men with Prostate Imaging Reporting and Data System (PI-RADS) >3 lesions based on PI-RADS v2 were included. Outcome measurements and statistical analysis: Patients were analyzed for potential treatment by FT and hemiablation. MRI lesions were mapped according to prostatic zones. Results and limitations: In total, 2371 patients were analyzed. According to consensus criteria (biopsy-proven unifocal lesion of International Society of Urological Pathology [ISUP] grade group <2, prostate-specific antigen [PSA] <15 ng/mL, and life expectancy >10 yr), 303 patients (12.8%; ISUP 1: n = 148 [6.2%]; ISUP 2: n = 155 [6.5%]) were potential candidates for FT. A maximum PSA level of <10 ng/mL would exclude further 60 (2.5%) of these men. The eligibility for hemiablation is slightly higher (16.2%). Unifocal lesions (n = 288) were equally distributed within the prostate (anteriorly [31%], apically [29%], and dorsally [36%]). Conclusions: With adherence to consensus statements, only a minority of PCa patients present as potential candidates for FT. Distribution of tumor localization suggests the need for different energy modalities to warrant an optimal FT treatment. Patient summary: We analyzed how many men who receive a magnetic resonance imaging-targeted and systematic prostate biopsy are candidates for the experimental focal therapy of the prostate. When following expert recommendations, only a small number of men are potential candidates for this alternative treatment. (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACTIVE SURVEILLANCE; CONSENSUS; ABLATION; RISK; Biopsy; Consensus; Eligibility criteria; Focal therapy; Focal therapy modalities; Hemiablation; Multiparametric magnetic resonance imaging; Patient selection; Partial ablation; Prostate neoplasms |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Sep 2022 08:20 |
| Last Modified: | 26 Sep 2022 08:20 |
| URI: | https://pred.uni-regensburg.de/id/eprint/47958 |
Actions (login required)
 |
View Item |
